Imperatae rhizoma-Hedyotis diffusa Willd. herbal pair alleviates nephrotic syndrome by integrating anti-inflammatory and hypolipidaemic effects

Phytomedicine ◽  
2021 ◽  
pp. 153644
Author(s):  
Wei Zou ◽  
Yaqian Dong ◽  
Shicong Yang ◽  
Linna Gong ◽  
Yan Zhang ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Hedyotis Diffusa ◽  
Anti Inflammatory

Nephrotic Syndrome Associated With Nonsteroidal Anti-inflammatory Drug Use in Two Children

PEDIATRICS ◽  
1990 ◽  
Vol 85 (5) ◽  
pp. 844-847
Author(s):  
Joan Robinson ◽  
Peter Malleson ◽  
David Lirenman ◽  
James Carter
Keyword(s):  
Renal Failure ◽  
Nephrotic Syndrome ◽  
Drug Use ◽  
Renal Disease ◽  
Interstitial Nephritis ◽  
Renal Toxicity ◽  
Plasma Creatinine ◽  
Over The Counter ◽  
Inflammatory Drug ◽  
Anti Inflammatory

Two children with nephrotic syndrome in association with nonsteroidal anti-inflammatory drug (NSAID) use are described, and the literature concerning this association is reviewed. NSAIDs are drugs with the potential for causing significant renal toxicity including the nephrotic syndrome, interstitial nephritis, and renal failure even in children without obvious preceding renal disease. Children prescribed such drugs should be regularly monitored with urinalyses and plasma creatinine estimations. The possibility of toxicity to over-the-counter use of NSAIDs should be remembered.

scholarly journals Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users

2019 ◽  
Vol 14 (9) ◽  
pp. 1355-1362 ◽  
Author(s):  
Mohammad Bakhriansyah ◽  
Patrick C. Souverein ◽  
Martijn W.F. van den Hoogen ◽  
Anthonius de Boer ◽  
Olaf H. Klungel
Keyword(s):  
Acetic Acid ◽  
Nephrotic Syndrome ◽  
Relative Risk ◽  
Propionic Acid ◽  
Drug Users ◽  
Control Group ◽  
Syndrome Diagnosis ◽  
Anti Inflammatory ◽  
Chemical Groups ◽  
Diagnosis Date

Background and objectivesNonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with AKI. Their association with nephrotic syndrome has not been systematically studied. This study aimed to assess the risk of nephrotic syndrome associated with NSAID use.Design, setting, participants, & measurementsA matched case-control study was performed in the UK primary care database. Cases were patients with a first diagnosis of nephrotic syndrome and controls were those without nephrotic syndrome. NSAID exposure (grouped either based on cyclooxygenase enzyme selectivity and chemical groups) was classified as either current (use at the nephrotic syndrome diagnosis date and corresponding date in the control group), recent, or past use. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using unconditional logistic regression analysis.ResultsWe included 2620 cases and 10,454 controls. Compared with non-use, current use of 15–28 days and >28 days of conventional NSAIDs was associated with a higher relative risk of nephrotic syndrome: adjusted OR, 1.34; 95% CI, 1.06 to 1.70, and OR, 1.42; 95% CI, 0.79 to 2.55, respectively. Also, recent use (discontinuation 1–2 months before nephrotic syndrome diagnosis date; OR, 1.55; 95% CI, 1.11 to 2.15) and past use (discontinuation 2 months-2 years; OR, 1.24; 95% CI, 1.07 to 1.43), but not current use of <15 days (OR, 0.78; 95% CI, 0.46 to 1.31) nor past use (discontinuation >2 years; OR, 0.96; 95% CI, 0.85 to 1.09) were associated with a higher relative risk of nephrotic syndrome as well as past use of selective COX-2 inhibitors (discontinuation 2–24 months; OR, 1.24; 95% CI, 0.98 to 1.58). Categorization based on chemical groups showed that acetic acid and propionic acid derivatives were associated with a higher risk of nephrotic syndrome.ConclusionsThe use of conventional NSAIDs was associated with a higher risk of nephrotic syndrome starting from at least 2 weeks of exposure, as well as for recent and past exposure up to 2 years before the diagnosis of nephrotic syndrome. This higher risk appeared mainly attributable to acetic acid and propionic acid derivatives.

Nephrotic Syndrome Associated with Use of the Nonsteroidal Anti-Inflammatory Drugs

Nephron ◽  
1984 ◽  
Vol 37 (3) ◽  
pp. 174-179 ◽  
Author(s):  
Donald A. Feinfeld ◽  
Ludmilla Olesnicky ◽  
Conrad L. Pirani ◽  
Gerald B. Appel
Keyword(s):  
Nephrotic Syndrome ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Ethyl Acetate Fraction from Hedyotis diffusa plus Scutellaria barbata Exerts Anti-Inflammatory Effects by Regulating miR-155 Expression and JNK Signaling Pathway

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Yuan Xu ◽  
Xiao-Xia Chen ◽  
Yi-Xin Jiang ◽  
Dan-Dan Zhang
Keyword(s):  
Ethyl Acetate ◽  
Signaling Pathway ◽  
Ethyl Acetate Fraction ◽  
Equal Weight ◽  
Dependent Manner ◽  
Jnk Signaling ◽  
Scutellaria Barbata ◽  
Hedyotis Diffusa ◽  
Jnk Signaling Pathway ◽  
Anti Inflammatory

Hedyotis diffusa Willd and Scutellaria barbata D. Don (HDSB) were the core couplet in medicines that were commonly used for the purpose of anti-inflammation and anticancer treatments in China. However, biological properties of this couplet have not been fully elucidated. In this study, we screened fractions of HDSB for their anti-inflammatory activities and explored pertinent molecular mechanisms on murine macrophage RAW264.7 cell model. Ethyl acetate fraction from the aqueous extract of the couplet at equal weight ratio (EA11) showed the strongest inhibition of the nitrite accumulation in supernatant of RAW264.7 cells stimulated with lipopolysaccharide (LPS)/interferon-γ (IFN-γ). In addition, EA11 inhibited iNOS and IL-1β expression in a concentration-dependent manner while promoting the expression of HO-1 and PPAR-γ. Anti-inflammatory capability is most likely facilitated by its inhibitory effect on JNK signaling pathway and miR-155 expression. This study suggests that EA11 may be represented as a potential anti-inflammatory therapeutic candidate.

scholarly journals A novel biomimetic nanomedicine system with anti-inflammatory and anti-osteoporosis effects improves the therapy efficacy of steroid-resistant nephrotic syndrome

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Jian Li ◽  
Mingyi Zhao ◽  
Xinying Xiang ◽  
Qingnan He ◽  
Rong Gui
Keyword(s):  
Nephrotic Syndrome ◽  
Glycyrrhizic Acid ◽  
Immune Escape ◽  
Platelet Membrane ◽  
Steroid Resistance ◽  
Inflammatory Factors ◽  
Steroid Resistant ◽  
Steroid Resistant Nephrotic Syndrome ◽  
Anti Inflammatory

AbstractClinically, steroid-resistant nephrotic syndrome (SRNS) is always prolonged and difficult to treat and easily develops into end-stage renal disease, resulting in a low survival rate. Strategies to reverse steroid resistance and reduce the long-term use of high doses of steroid medicines are urgently needed. In this study, a novel nanoparticle drug system (Pm-GCH) with a core–shell structure was designed. Metal–organic frameworks, synthesized by glycyrrhizic acid (G) and calcium ions (Ca2+) loaded with hydrocortisone (H) were the core of the nanoparticles. Platelet membrane vesicles were the shells. The natural platelet membrane endows Pm-GCH with good biocompatibility and the ability to promote immune escape. In addition, under the chemotaxis of inflammatory factors, platelet membranes assist Pm-GCH in nonspecific targeting of the inflammatory sites of the kidney. Under an inflammatory acid environment, GCH slowly degrades and releases glycyrrhizic acid and hydrocortisone. Glycyrrhizic acid inhibits the inactivation of hydrocortisone, jointly inhibits the activity of phospholipase A2 (PLA2) and the classic activation pathway of complement C2, blocks the production of inflammatory factors, plays an anti-inflammatory role, and enhances the efficacy of hydrocortisone in the treatment of SRNS. Moreover, glycyrrhizic acid alleviates osteoporosis induced by long-term use of glucocorticoids. These results indicate that Pm-GCH is a promising treatment strategy for SRNS. Graphical Abstract

Reversible Renal Failure and Nephrotic Syndrome Associated with Nonsteroidal Anti-Inflammatory Drugs

1979 ◽  
Vol 301 (23) ◽  
pp. 1271-1273 ◽  
Author(s):  
Joseph H. Brezin ◽  
Sheila Moriber Katz ◽  
Allen B. Schwartz ◽  
Joel L. Chinitz
Keyword(s):  
Renal Failure ◽  
Nephrotic Syndrome ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Glomerular Tip Lesion Associated With Nonsteroidal Anti-Inflammatory Drug–Induced Nephrotic Syndrome

2005 ◽  
Vol 46 (4) ◽  
pp. e55-e58 ◽  
Author(s):  
Inderpreet Sekhon ◽  
Sandeep Munjal ◽  
Byron Croker ◽  
Richard J. Johnson ◽  
A. Ahsan Ejaz
Keyword(s):  
Nephrotic Syndrome ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Anti Inflammatory

scholarly journals INFLUENCE OF ACECLOFENAK ON THE LEVEL OF PROAND ANTIINFLAMMATORY CYTOKINES IN THE PATIENTS WITH RHEUMATOID ARTHRITIS AND CHRONIC KIDNEY DISEASE

2015 ◽  
pp. 17-21
Author(s):  
O. Zubl ◽  
W. Roborchuks ◽  
G. Dotsyukl
Keyword(s):  
Rheumatoid Arthritis ◽  
Chronic Kidney Disease ◽  
Nephrotic Syndrome ◽  
Kidney Disease ◽  
Inflammatory Cytokines ◽  
Stage I ◽  
Complex Treatment ◽  
Inflammatory Drug ◽  
Ckd Stage ◽  
Anti Inflammatory

 The purpose - to investigate the effect of aceclofenac on the level of proand anti - inflammatory cytokines in patients with rheumatoid arthritis and chronic kidney disease. Material and Methods: The research included 88patients: 45 with rheumatoid arthritis (RA) without chronic kidney disease (CKD), 43 with RA and CKD stage I without nephrotic syndrome. In a complex therapie of patients it is included nonsteroid anti - inflammatory drug aceclofenac. Influence of aceclofenac was compared with meloxicam. It is investigated to patients the content IL - 1$, IL - 10, TNFa, TGF$1, MCP - 1 is the urine with an immunofermental method. Results. After two weeks of therapy with aceclofenac was revealed reduction IL - 1$ levels (p<0,05) and urinary (p<0,05), TNFa levels (p<0,05) in patients with RA and RA with CKD. Level of pro - sclerous cytokin TGFf>1 of blood (p<0,05) and urine (p<0,001) at patients with RA with CKD is reduced. Decrease in the MCP - 1 level in blood (in 1,5 times) and in urine (in 2 times) at patients with RA and CKD is revealed. Conclusion. Application of therapy with aceclofenac for complex treatment ofpatients with RA and CKD improves efficiency of treatment for these patients through improvement cytokines of blood and urine.  

Sign in / Sign up

Export Citation Format

Share Document